2023
August 2023 − Metaclipse Therapeutics receives FDA clearance of its 2nd IND for its Membrex™ personalized immunotherapy in head and neck cancer. Metaclipse received clearance from the U.S. Food and Drug Administration (FDA) for its 2nd Investigational New Drug (IND) application to initiate a Phase 1 clinical study of its personalized immunotherapy platform, Membrex™, in combination with an approved immune checkpoint inhibitor (ICI) for the treatment of recurrent and advanced metastatic head and neck squamous cell carcinoma (HNSCC) on August 23, 2023.
July 2023 − Metaclipse Therapeutics signs a MOU with Syntekabio. Metaclipse Therapeutics signed a MOU with Syntekabio, an Artificial Intelligence (AI) based drug development company, for joint research on development of a personalized immunotherapy for cancer. With this MOU, Syntekabio plans to support Metaclipse in conducting research on neoantigen identification for its Membrex™ personalized cancer vaccine platform. After this agreement, the two companies plan to comprehensively analyze Syntekabio’s neoantigen prediction results and Metaclipse’s clinical trial results to evaluate the correlation between the neoantigen profile and treatment response and to conduct joint research to identify potent individual neoantigens that demonstrate high immunogenicity among the many antigens loaded in the Membrex™ vaccine. More information can be found in the announcement here.
May 2023 – Winship Cancer Institute announces new NCI R01 grant to evaluate Metaclipse’s Membrex™ vaccine immunotherapy with Phase 1 clinical trial for head and neck cancer. Winship Cancer Institute (Emory University) members, Dr. Dong Moon Shin, MD and Dr. Periasamy Selvaraj, PhD, in collaboration with Metaclipse Therapeutics, received a five-year, $3.1M grant from the National Cancer Institute to evaluate a novel, personalized vaccine immunotherapy to help more patients with head and neck cancer benefit from immune checkpoint therapies. This award provides funding for a Phase 1 dose-escalation clinical trial of Membrex™ alone and in combination with immune checkpoint inhibitors in recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).
April 2023 − Metaclipse Therapeutics receives FDA clearance of its IND for a first-in-human Phase 1 clinical trial of Membrex™ in triple negative breast cancer (TNBC). Metaclipse obtained clearance of its investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of its personalized immunotherapy platform, Membrex™, in combination with an approved immune checkpoint inhibitor for the treatment of early stage and metastatic triple negative breast cancer (TNBC) on April 5, 2023.
2021
September 2021 − Metaclipse Therapeutics is awarded $2 million by NCI to support a phase 1 clinical trial of Membrex™ in triple negative breast cancer (TNBC). Metaclipse Therapeutics is awarded $2 million by the National Cancer Institute (NCI) to support a phase 1 clinical trial to evaluate its personalized immunotherapy platform, Membrex™ in combination with immune checkpoint inhibition in early stage and metastatic triple negative breast cancer (TNBC), in partnership with Winship Cancer Institute and Emory University.
April 2021 − Shaker J.C. Reddy, the President and Co-Founder of Metaclipse Therapeutics, is awarded the 2021 Golden Helix Community award from Georgia Bio.
2020
November 2020 − Metaclipse presents at the Life Sciences Summit 2020 Virtual Conference held on November 17-18, 2020.
October 2020 − Metaclipse Therapeutics participates in the NIH Innovation Conference on October 13, 2020.
July 2020 − Metaclipse is selected to participate in the NCI Small Business SBIR Innovation Research (SBIR) Investor Initiatives Program.
June 2020 − Metaclipse Therapeutics is awarded a $2.2M SBIR Phase II contract to develop a SARS-CoV-2 vaccine for the elderly.
2019
October 2019 − Metaclipse Therapeutics participates in Georgia Bio Innovation Summit in Atlanta, Georgia on October 8, 2019.
September 2019 − Metaclipse Therapeutics receives SBIR Contract Phase II award for influenza vaccine development for the elderly. This product development award from the NIAID/NIH in September for $1.95M supports cGMP vaccine production efforts, further preclinical studies to assess immune response and viral challenge, as well as vaccine safety studies.
August 2019 − Metaclipse Therapeutics completes an independent GLP-compliant toxicology/safety study of its personalized immunotherapy, Membrex™. The study performed by IIT Research Institute (Chicago, IL), was conducted in mice on the vaccine alone and in combination with immune checkpoint inhibitors. No adverse related events are detected other than injection site cell infiltration.
May 2019 − Metaclipse Therapeutics participates in the Pharmaceutical & BioScience Society (PBSS) Workshop on CMC Development for Biologics in Foster City, California.
March 2019 − Metaclipse Therapeutics obtains exclusive worldwide rights to the platform technology from Emory University.
January 2019 − Metaclipse Therapeutics receives an SBIR Diversity Supplement award from the NCI/NIH. This award supports the career development of under-represented scientists from minority backgrounds and additional process development studies.
2018
October 2018 − Metaclipse Therapeutics attends the National Institute on Drug Abuse (NIDA)-sponsored Vaccines for the Treatment of Opioid Abuse Disorder conference in Bethesda, Maryland on October 23-24.
2017
December 2017 − Metaclipse presents at the 3rd WSGR Healthcare Innovations Venture Investment Forum. The forum, co-hosted by Wilson Sonsini Goodrich & Rosati (WSGR) and the University of Texas in Austin’s Dell Medical School, was held in Austin, Texas on December 6-8, 2017.
September 2017 − Metaclipse Therapeutics receives an SBIR Phase II award from the NCI/NIH for $1.86M. This Small Business Innovation Research (SBIR) product development award from the National Cancer Institute (NCI)/ National Institutes of Health (NIH) supports dose finding, safety studies, and cGMP-compliant process development activities of Metaclipse’s personalized immunotherapy platform technology.
August 2017 − Metaclipse receives an SBIR Phase I contract award for influenza vaccine development for the elderly. This Small Business Innovation Research (SBIR) award for $230,000 from the National Institute of Allergy and Infectious Disease (NIAID) supports preclinical studies to assess immune response and viral challenge of Metaclipse’s influenza vaccine utilizing membrane-anchored biological adjuvants.
March 2017 − Metaclipse Therapeutics conducts a pre-IND meeting with the FDA. Metaclipse held a pre-IND meeting with the Center for Biologics Evaluation and Research (CBER) to discuss CMC and safety study design of the personalized immunotherapy product.
2016
June 2016 − Metaclipse Therapeutics participates in the 2016 BIO International Convention. The convention was hosted by the Biotechnology Industry Organization (BIO) in San Francisco, California on June 6-9, 2016.
March 2016 − Metaclipse Therapeutics, with Emory University, receives a 5-year R01 Academia/Industry partnership award for $2.5M. This proposal, funded through the NCI, investigates Metaclipse’s Membrex™ immunotherapy in combination with immune checkpoint inhibitors in humanized mouse models.
January 2016 − Metaclipse Therapeutics attends the JP Morgan 34th Annual Healthcare Conference in San Francisco, California on January 11-15, 2016.
2015
Late 2015 − Metaclipse Therapeutics is accepted into the Johnson & Johnson Innovation JLABS program. Metaclipse is accepted as a resident at JLABS @ TMC incubator in Houston, Texas.
Late 2015 − Metaclipse Therapeutics presents to the Bio/Med Investor Network. The Bio/Med Investor Network is an angel network that makes early-stage investments in biomedical, medtech and healthcare-related companies.
November 2015 − Metaclipse Therapeutics presents at the 2015 CPRIT (Cancer Prevention and Research Institute of Texas) Conference. Metaclipse presents a poster at the Innovations in Cancer Prevention and Research Conference hosted by the Cancer Prevention and Research Institute of Texas in Austin, Texas on November 10, 2015.
November 2015 − Metaclipse Therapeutics presents at the Georgia Bio Innovation Summit. The annual summit, hosted by Georgia Bio, was held Atlanta, Georgia on November 2, 2015.
2015 − Metaclipse Therapeutics receives funding from the Georgia Research Alliance for product development.
2015 − Metaclipse Therapeutics receives a grant from the Wallace H. Coulter Foundation.
2015 − Metaclipse Therapeutics presents at the 6th Global Atlanta Forum organized by the Georgia Indo-American Chamber of Commerce (GIACC).
2014
September 2014 − Metaclipse Therapeutics presents at the first USA-India Forum on Vaccines and Immunotherapy (UIFVI). The forum, held in Atlanta, Georgia, was organized by the USA-India Business Summit (UIBS) in partnership with Emory Vaccine Center, The University of Georgia, and the Center for Immunoengineering of Georgia Tech.
June 2014 − Metaclipse Therapeutics participates in the 2014 BIO International Convention. The convention, hosted by the Biotechnology Industry Organization (BIO), drew 15,667 industry leaders in San Diego, California on June 23-26, 2014.
February 2014 − Metaclipse Therapeutics is selected for the NIH Niche Assessment Program. The National Institute of Health’s Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Niche Assessment Program is a nationwide program funded by NIH to assess the technology and market potential.
2013
August 2013 − Metaclipse Therapeutics receives a Small Business Innovation Research (SBIR) Phase I award from the National Cancer Institute (NCI). Metaclipse Therapeutics received $150,000 of SBIR Phase I funding to develop their personalized immunotherapy for the treatment of triple negative breast cancer (TNBC).
2012
October 2012 − Metaclipse Therapeutics presents at the 11th Annual Georgia Life Sciences Summit. The Southeast region’s largest bioscience conference, sponsored by Georgia Bio, was held at the Georgia International Convention Center in Atlanta, Georgia on October 3, 2012.